Relative effects of statin therapy on stroke and cardiovascular events in men and women: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

Stroke

Volumn 39, Issue 9, 2008, Pages 2444-2448

  Goldstein, Larry B ^a,j   Amarenco, Pierre ^b   Lamonte, Marian ^c   Gilbert, Steven ^d   Messig, Michael ^e   Callahan, Alfred ^f   Hennerici, Michael ^g   Sillesen, Henrik ^h   Welch, K Michael A ⁱ  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF MARYLAND   (United States)

^d Rho Inc   (United States)

^e Neurologic Consultants ^*

^f Neurologic Consultants   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Lipids; Prevention; Sex; Statins; Stroke; TIA

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN; APOLIPOPROTEIN A1; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; BLOOD; BLOOD PRESSURE; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REPRODUCIBILITY; SEXUAL DEVELOPMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL;

APOLIPOPROTEIN A-I; BLOOD PRESSURE; CHOLESTEROL; DATA INTERPRETATION, STATISTICAL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; PYRROLES; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS; SEX FACTORS; STROKE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 52449106211     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.513747     Document Type: Article

References (11)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
2. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387-392.
3. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
4. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graf-fagnino CA, Harrington RA, White HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37:1427-1431.
5. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
6. The SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovascular Diseases. 2003;16:389-395.
7. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
8. Harrell F, Lee K, Mark D. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat in Med. 1996;15:361-387.
9. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with prava-statin. The Cholesterol and Recurrent Events (CARE) study. Circulation. 1999;99:216-223.
10. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pavastatin in Ischaemic Disease (LIPID) study group. N Engl J Med. 1998;339:1349-1357.
11. Bushnell CD, Hurn P, Colton C, Miller VM, del Zoppo G, Elkind MSV, Stern B, Herrington D, Ford-Lynch G, P. G., James A, Brown CM, Choi E, Bray P, Newby LK, Goldstein LB, Simpkins J. Advancing the study of stroke in women. Summary and recommendations for future research from an NINDS-sponsored multidisciplinary working group. Stroke. 2006;37:2387-2399.